Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Jole Ventriglia
Observed names:
J. Ventriglia,
JOLE VENTRIGLIA,
Ventriglia J
Institution:
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"
Observed institutions:
University of Campania "Luigi Vanvitelli",
Federico II University Hospital,
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale",
Istituti di Ricovero e Cura a Carattere Scientifico,
University of Naples Federico II
ORCID:
0000-0002-8160-5014
Observed ORCID:
0000-0002-8160-5014
OpenAlex ID:
A5019880542
Immunotherapy in ovarian, endometrial and cervical cancer: State of the art and future perspectives
2017
·
Jole Ventriglia
, Immacolata Paciolla
, et al.
·
Cancer Treatment Reviews
·
158
Triple-Negative Breast Cancers: Systematic Review of the Literature on Molecular and Clinical Features with a Focus on Treatment with Innovative Drugs
2018
·
Anna Diana
, Elisena Franzese
, et al.
·
Current Oncology Reports
·
103
Neutrophil to lymphocyte ratio (NLR) for prediction of distant metastasis-free survival (DMFS) in early breast cancer: a propensity score-matched analysis
2016
·
Michele Orditura
, Gennaro Galizia
, et al.
·
ESMO Open
·
92
PDF
Inflammatory Indexes as Prognostic and Predictive Factors in Ovarian Cancer Treated with Chemotherapy Alone or Together with Bevacizumab. A Multicenter, Retrospective Analysis by the MITO Group (MITO 24)
2018
·
Alberto Farolfi
, Micaela Petrone
, et al.
·
Targeted Oncology
·
73
Significance of PD-L1 in Metastatic Urothelial Carcinoma Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
2024
·
Brigida Anna Maiorano
, Massimo Di Maio
, et al.
·
JAMA Network Open
·
67
NAB-paclitaxel and gemcitabine in metastatic pancreatic ductal adenocarcinoma (PDAC): from clinical trials to clinical practice
2016
·
Ferdinando De Vita
, Jole Ventriglia
, et al.
·
BMC Cancer
·
63
PDF
Pancreatic neuroendocrine tumors: Nosography, management and treatment
2015
·
Michele Orditura
, Angelica Petrillo
, et al.
·
International Journal of Surgery
·
58
PDF
Targeting immunometabolism mediated by the IDO1 Pathway: A new mechanism of immune resistance in endometrial cancer
2022
·
Anna Passarelli
, Carmela Pisano
, et al.
·
Frontiers in Immunology
·
40
PDF
Neutrophil to Lymphocyte Ratio as a Predictor of Poor Prognosis in Metastatic Pancreatic Cancer Patients Treated with Nab-Paclitaxel plus Gemcitabine: A Propensity Score Analysis
2018
·
J. Ventriglia
, A. Petrillo
, et al.
·
Gastroenterology Research and Practice
·
39
PDF
Ramucirumab as Second-Line Therapy in Metastatic Gastric Cancer: Real-World Data from the RAMoss Study
2018
·
Maria Di Bartolomeo
, Monica Niger
, et al.
·
Targeted Oncology
·
39
PARP inhibitors (PARPi) prolongation after local therapy for oligo-metastatic progression in relapsed ovarian cancer patients
2023
·
Thibault Gauduchon
, Maria Kfoury
, et al.
·
Gynecologic Oncology
·
36
PDF
Endometrial cancer in the elderly: Characteristics, prognostic and risk factors, and treatment options
2024
·
Miriam Forte
, Sabrina Chiara Cecere
, et al.
·
Critical Reviews in Oncology/Hematology
·
35
Immunotherapy in Penile Squamous Cell Carcinoma: Present or Future? Multi-Target Analysis of Programmed Cell Death Ligand 1 Expression and Microsatellite Instability
2022
·
Marco Montella
, Rosalaura Sabetta
, et al.
·
Frontiers in Medicine
·
29
First line nab-paclitaxel plus gemcitabine in elderly metastatic pancreatic patients: a good choice beyond age
2019
·
Angelica Petrillo
, Annalisa Pappalardo
, et al.
·
Journal of Gastrointestinal Oncology
·
25
PDF
Impact of COVID-19 outbreak on cancer immunotherapy in Italy: a survey of young oncologists
2020
·
Margaret Ottaviano
, Marcello Curvietto
, et al.
·
Journal for ImmunoTherapy of Cancer
·
20
PDF
Trabectedin in Ovarian Cancer: is it now a Standard of Care?
2018
·
J. Ventriglia
, I. Paciolla
, et al.
·
Clinical Oncology
·
20
Systemic-Inflammation-Based Score can Predict Prognosis in Metastatic Gastric Cancer Patients Before First-Line Chemotherapy
2018
·
Angelica Petrillo
, Maria Maddalena Laterza
, et al.
·
Future Oncology
·
19
Serum Insulin-Like Growth Factor 1 Correlates with the Risk of Nodal Metastasis in Endocrine-Positive Breast Cancer
2013
·
F. Morgillo
, F. De Vita
, et al.
·
Current Oncology
·
19
PDF
The emerging role of PARP inhibitors in prostate cancer: A narrative review
2025
·
Lorenzo Lobianco
, Gabriele Calvanese
, et al.
·
Cancer Treatment Reviews
·
16
PDF
Effect of bevacizumab in advanced low grade serous ovarian cancer: Data from the MITO 22 trial
2023
·
Lucia Musacchio
, Margherita Turinetto
, et al.
·
Gynecologic Oncology
·
15
The way to precision medicine in gynecologic cancers: The first case report of an exceptional response to alpelisib in a PIK3CA-mutated endometrial cancer
2023
·
Anna Passarelli
, Jole Ventriglia
, et al.
·
Frontiers in Oncology
·
13
PDF
Efficacy of PARP inhibitors in advanced high-grade serous ovarian cancer according to BRCA domain mutations and mutation type
2024
·
Roberto Buonaiuto
, Giuseppe Neola
, et al.
·
Frontiers in Oncology
·
12
PDF
The immunotherapy era in ovarian clear cell carcinoma: current evidence and future perspective
2025
·
Anna Passarelli
, Sabrina Chiara Cecere
, et al.
·
Frontiers in Immunology
·
10
PDF
2335 Analysis of activity, efficacy and safety of first line Nab Paclitaxel (Nab-P) and Gemcitabine (G) in advanced pancreatic cancer (APDAC) frail and elderly patients (pts)
2015
·
G. Giordano
, F. De Vita
, et al.
·
European Journal of Cancer
·
8
Olaparib as a rescue treatment in platinum-refractory germ-cell tumors: the IGG-02 phase II trial
2025
·
G. Schepisi
, M. Urbini
, et al.
·
ESMO Open
·
7
PDF
Show more works
View as search
Works count:
69
Citation count:
1,074
H-index:
18
I10-index:
23
Year
Topic
Type